Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design-Reference-Cited by-同舟云学术

Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design

Published:2015-05 Issue:5 Volume:38 Page:259-266
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Bulluck Heerajnarain¹²³,Fröhlich Georg M.⁴⁵,Mohdnazri Shah⁵,Gamma Reto A.⁵,Davies John R.⁵,Clesham Gerald J.⁵,Sayer Jeremy W.⁵,Aggarwal Rajesh K.⁵,Tang Kare H.⁵,Kelly Paul A.⁵,Jagathesan Rohan⁵,Kabir Alamgir⁵,Robinson Nicholas M.⁵,Sirker Alex¹,Mathur Anthony⁶,Blackman Daniel J.⁴,Ariti Cono⁷⁸,Krishnamurthy Arvindra⁴,White Steven K.¹²³,Meier Pascal¹,Moon James C.¹²,Greenwood John P.⁴,Hausenloy Derek J.²³⁹¹⁰

Affiliation:

1. Department of Cardiology; Heart Hospital; London United Kingdom

2. National Institute of Health Research; University College London Hospitals Biomedical Research Centre; London United Kingdom

3. Hatter Cardiovascular Institute; Institute of Cardiovascular Science; London United Kingdom

4. Department of Cardiology; Leeds General Infirmary; Leeds United Kingdom

5. Department of Cardiology; Essex Cardiothoracic Center; Nethermayne, Basildon United Kingdom

6. London Department of Cardiology; Chest Hospital; London United Kingdom

7. Nuffield Health Trust; London United Kingdom

8. London School of Hygiene and Tropical Medicine; London United Kingdom

9. Cardiovascular and Metabolic Disorders Program; Duke-National University of Singapore; Singapore

10. National Heart Research Institute Singapore; National Heart Centre Singapore; Singapore

Funder

Rosetrees Trust

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference40 articles.

1. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;O'Gara;J Am Coll Cardiol,2013

2. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction;Spencer;Circulation,2002

3. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals;Dobrzycki;Eur Heart J,2007

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials;European Heart Journal;2024-01-09

2. VWF, CXCL8 and IL6 might be potential druggable genes for acute coronary syndrome (ACS);Computational Biology and Chemistry;2019-12

3. Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial;American Heart Journal;2019-05

4. Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction;Medicine;2018-12

5. Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure;JAMA Internal Medicine;2018-07-01